DKmedtech Named a 2024 Jiangsu Potential Unicorn Enterprise and Files IPO Prospectus
DK Medtech
Vascular Interventional Balloon Product Developer
Recently, the Jiangsu Productivity Promotion Center released the 2024 evaluation results of unicorn and gazelle enterprises in Jiangsu. DK Medtech was successfully selected as a "2024 Jiangsu Potential Unicorn Enterprise."
As a rapidly growing medical device company in Jiangsu Province, DK Medtech has always adhered to innovation as the driving force and quality as the essence of life since its establishment. The company is committed to developing and producing high-quality vascular intervention products. Its product line covers multiple fields including coronary intervention, peripheral intervention, and neurointervention, with several products having gained recognition and approval in both domestic and international markets.
The rapid growth of DK Medtech is attributed to its continuous investment in research and development and keen insight into market demands. The company not only has a strong R&D team led by seasoned industry experts but also maintains close cooperative relationships with many well-known medical institutions both domestically and internationally, jointly promoting the advancement and application of vascular interventional treatment technologies.
The recognition as a potential unicorn enterprise in Jiangsu this time is a full affirmation of DK Medtech's achievements in market valuation, technological innovation, market expansion, and team building. As one of the members, DK Medtech will continue to uphold the business philosophy of "innovation, quality, and service," continuously enhance product competitiveness, and provide global patients with higher-quality medical solutions.
Looking to the future, DK Medtech CEO Weng Yulin stated: "We will continue to increase R&D investment, expand our product lines, and further enhance DK Medtech's global influence through international cooperation and market expansion. We are confident that within the next few years, DK Medtech will achieve a remarkable transformation from a potential unicorn to a true unicorn."
DK Medtech
DKmedtech
DK Medical Technology Co., Ltd. (hereinafter referred to as "DK Medtech") was founded in 2015 by Mr. Weng Yulin and is headquartered in Suzhou City, Jiangsu Province. DK Medtech is committed to improving patients' quality of life through leading technology and innovative medical solutions. Its current product lines cover fields such as coronary intervention, peripheral intervention, and neurointervention, aiming to provide high-quality medical solutions for patients worldwide.
Since its establishment, DK Medtech has always adhered to innovation as its driving force and has now become a leading full-category vascular intervention innovator in China. The company has developed more than ten types of balloon catheters, including standard balloons, high-pressure balloons, scoring balloons, and drug-coated scoring balloons. Its product portfolio covers nearly all demands in the field of vascular intervention, including cardiovascular, peripheral, and neurovascular interventions. Through its self-developed directional scoring technology, which is utilized in coronary scoring balloons, peripheral scoring balloons, and drug-coated scoring balloons, pre-market RCT studies have shown that their clinical performance demonstrates significantly better clinical benefits compared to imported control groups. This has allowed DK Medtech to achieve outstanding results and market position in niche markets. Additionally, the company has signed multiple strategic cooperation agreements with well-known foreign enterprises such as Medtronic and Asahi Intecc.
DK Medtech has built a team of over 300 people covering R&D, operations, management, and sales, with a 12,000㎡ global manufacturing center and a 9,200㎡ R&D office center. To date, DK Medtech has been honored with awards such as "National Specialized, Fine, Distinctive, and Innovative Little Giant Enterprise," "National High-Tech Enterprise," "Jiangsu Province Potential Unicorn Enterprise," "Suzhou Unicorn Cultivation Enterprise," "Suzhou Engineering Technology Center," VB "Top 100 Future Healthcare Companies in 2024," "2024 Medical Health Industry Innovation Power Product List," "China Medical Device 2024 Star Exploration Innovation List," "Top 100 Sharp Companies of the CV Awards 2023," "Venture50 (Influential List, Life & Health List) 2023," and "Top 14 in the 8th China Innovation and Entrepreneurship Competition." The company holds certifications including ISO:13485 Quality Management System, MDSAP, and Intellectual Property Compliance Management System (GB/T29490-2023). It has also participated in drafting multiple national and industry standards, such as "Guidelines for the Release of Parameters in Ethylene Oxide Sterilization Processes for Medical Devices" and "Test Methods for Coating Adhesion of Intravascular Catheter Guide Wires."
At the same time, the company has gained wide favor from social capital. Up to now, it has undergone six rounds of financing, cumulatively receiving hundreds of millions of yuan in funding from well-known investment institutions such as Qiming Venture Partners, Legend Capital, Oriza Seed Fund, CICC Capital, and GaoTeJia Investment.
